Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled dose-ranging study of MSTT1041A in uncontrolled severe asthma
2016-001549-13Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing MSTT1041A with Placebo (2 arms). Started Sep 2016; status: completed.
02
Drugs
astegolimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-001549-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001549-13.